Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has worked faithfully but unsuccessfully to produce an one off therapy, variously called Pro 140, leronlimab, along with Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in phrases of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they will actually be used is an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as a combination treatment in the therapy of multi-drug-resistant HIV are actually closing.

I’m creating my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of my past several shares. My 1st CytoDyn article, “CytoDyn: What In order to Do When It is Too Good to be able to Be True?”, set away the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such a very marketing image in the Uptick Newswire interview which I came away with a bad impression of the business.

Irony of irony, the bad impression of mine of the business has grown steadily, although the disappointment has not been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger at the moment still disappoints? Therein sits the story; allow me to explain.

CytoDyn acquired its much-storied treatment (which I shall refer to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the therapy and prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s payment of $3.5 huge number of transfers ownership of the know-how and associated intellectual property from Progenics to CytoDyn, and also approximately twenty five million mg of bulk drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 million) and the very first new drug program approval ($5 million), as well as royalty payments of five % of net sales after commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to get a sector cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous indications and many therapies, it has this single treatments and a “broad pipeline of indications” since it puts it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a likely beneficial therapy of dozens of indications.

The opening banner of its on the site of its (below) shows an energetic business with diverse interests albeit centered on leronlimab, multiple disease types, multiple publications in addition to multiple presentations.

Might all this be smoke and mirrors? That’s a question I’ve been asking myself through the really start of the interest of mine in this business. Judging with the multiples of thousands of various commentary on listings accessible through Seeking Alpha’s CytoDyn Summary page, I’m far from alone in this question.

CytoDyn is a traditional battleground, or maybe some could say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *